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High-intensity focused ultrasound (HIFU) is a promising form of thermal ablation of benign 
thyroid nodules, but evidence supporting its use is scarce. The present review evaluated the 
efficacy and safety of single-session HIFU treatment of benign thyroid nodules. As reported in 
the literature, the extent of nodule shrinkage following treatment ranged from 48.8% to 68.8%. 
Like other forms of ablation, the shrinkage rate was greatest in the first 3-6 months, and the 
best responders were patients with small (≤10 mL) nodules. Complications were uncommon, 
but temporary vocal cord palsy occurred in 3%-4% of patients, and was related to the distance 
between the HIFU beam and the recurrent laryngeal nerve. Despite being safe and efficacious, a 
larger-scale prospective trial is required.
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Introduction
Thyroid nodules are common and can be discovered by clinical palpation in 5% of normal individuals 
and by high-resolution ultrasonography (US) up to 60% of the general population [1,2]. However, 
since most of these nodules (>90%) are benign and will remain relatively unchanged over time, 
observation and reassurance are normally recommended [3]. According to recent clinical practice 
guidelines, surgical resection is only indicated when a nodule becomes large (≥4 cm) or is causing 
obstructive and/or local pressure symptoms [1-3]. For years, surgical resection has remained the 
mainstay of treatment for large and/or symptomatic benign thyroid nodules because it is considered 
safe when done by an experienced surgeon. Nevertheless, surgical resection can lead to complications 
and is associated with high costs and a need for general anaesthesia. As a result, increasing 
interest has emerged in developing less invasive, non-surgical procedures for the treatment of large 
symptomatic benign thyroid nodules [4,5]. 
To date, a number of less invasive options, including ethanol ablation, laser ablation (LA), 
microwave ablation, and radiofrequency ablation (RFA) [5-7] have been described. Ethanol ablation 
has been shown to be effective for thyroid cysts and is recommended for recurrent, benign thyroid 
cysts [5,8]. However, for solid or predominantly solid (<30% cystic area) nodules, thermal ablation 
techniques such as LA and RFA are generally preferred [7,9,10]. Studies have found these thermal 
techniques not only can result in significant nodule size reduction, but also reduce nodule-related 
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symptoms in many patients [7,9-12]. 
High-intensity focused ultrasound (HIFU) is a new thermal 
ablation technique that is gaining popularity among clinicians [11]. 
However, relative to other thermal techniques, it has been less well 
described in the literature. Given the scarcity of the evidence, the 
aim of this review was to comprehensively evaluate the efficacy and 
safety of HIFU treatment of benign thyroid nodules.
High-Intensity Focused Ultrasound for 
Benign Thyroid Nodules
What is HIFU?
HIFU is a form of thermal ablation in which energy is delivered in 
the form of US waves extra-corporeally to a targeted area deep 
beneath the skin. Since energy can be delivered accurately under US 
guidance, the risk of damaging or injuring the surrounding tissues 
is small [13]. During treatment, multiple high-energy US waves are 
generated and focused at one particular area to induce thermal 
ablation. Direct damage to biological tissues usually takes two 
forms: the thermal effect and acoustic cavitation. In the thermal 
effect, the targeted tissue absorbs the US waves, which causes 
molecules to vibrate and/or rotate, leading to frictional heat [14]. 
When the tissue temperature reaches 56°C or above for a duration 
of 1 second, protein denaturation and coagulation necrosis begin [14].
Another form of damage is known as acoustic cavitation, in which 
microbubbles are formed from the US energy [15,16]. The negative 
pressure caused by the US waves on the tissue withdraws gas from the 
tissue, causing bubbles to form. These bubbles either oscillate according 
to the frequency of the US waves or expand gradually and collapse [17].
Other Biological Effects of HIFU
Apart from the direct thermal and cavitation effects, when tissues 
are exposed to lower-energy US, some cells stop proliferating and 
undergo some subtle cellular changes. For example, the cellular 
membrane becomes more permeable, leading to changes in the 
intracellular environment and intracellular electrolyte balance [18]. 
Other modifications include changes in intracellular proteins in 
locations where DNA synthesis and polymerization are controlled [13]. 
These changes cause slow cell death and, in turn, directly stimulate 
natural killer cells, CD8+ T cells, and dendritic cells. The resultant 
activity of these cells facilitates the detection and destruction of 
any remaining tumor cells both locally and systemically. Lastly, the 
thermal treatment can modify the vasculature of the tumor. The 
permeability of the tumor vasculature is increased [13]. Overall, low-
power HIFU ablation can sensitize tumors to the effects of radiation 
and chemotherapy, as well as enhancing local drug and gene delivery 
to tumors, and has an immune-stimulatory capacity [19].
Nodule Selection and Treatment Indications
In most instances, any thyroid nodule that has been confirmed to be 
benign on at least one occasion by fine-needle aspiration cytology 
or core needle biopsy is suitable for HIFU ablation. The ablation of 
follicular neoplasms or primary thyroid cancers is not recommended 
[20]. Some groups prefer to obtain two consecutive benign fine-
needle aspiration cytology results or one benign core needle biopsy 
before proceeding to ablation [21,22]. However, in our view, this 
may not be necessary, because the likelihood of malignancy in 
a nodule without suspicious clinical and US features and with 
benign cytology (i.e., Bethesda class II) is very small (<1%-2%) 
[2]. Table 1 compares the inclusion and exclusion criteria between 
different HIFU studies. One exclusion criterion worth highlighting is 
whether the patient must be able to extend his or her neck during 
treatment, because inadequate neck exposure or extension makes 
the placement of the treatment head on the patient’s neck difficult. 
The distance between the center of the nodule and the skin is also 
important, because nodules that are too near (≤5 mm) or too deep 
(≥3 cm) from the skin render the treatment unsafe and not feasible. 
Skin burns can occur when treating lesions close to the skin, while 
treatment is less effective for lesions located too deep.
In terms of treatment indications, one important consideration 
is that the nodule should be causing some physical symptoms or 
concerns, because most thyroid nodules do not cause symptoms 
and can be left untreated. In our practice, patient preference is 
considered a relative indication, because surgical resection remains the 
treatment of choice for symptomatic or rapidly growing benign nodules.
To allow for the more objective follow-up assessment of symptoms, 
using a 0- to 10-cm visual analog score is recommended before 
and after treatment. Cosmetic concerns can often be assessed by a 
1-4 grading score (1, no palpable nodule; 2, palpable but not visible 
nodule; 3, visible nodule on swallowing; 4, readily visible nodule) [22].
Technique and Equipment
Patients undergoing HIFU ablation are required to fast for at least 
4-6 hours before the procedure because the administration of 
intravenous sedation and analgesia may cause nausea or vomiting 
during or after the procedure. Prior to treatment, a fine-bore cannula 
(20F or 22F) is inserted to allow easy venous access for drug 
administration. For sedation and analgesia, intravenous pethidine 
(50-100 mg) (an opioid pain medication) and diazepam (5-10 mg) 
(a short-acting benzodiazepine) are administered together 5-10 
minutes before the procedure [23,24]. Although most patients feel 
some pain and discomfort in the ablation area during treatment 
because the US energy needs to propagate through the skin, the 
pain is usually tolerable, and in our experience, it is unusual to have 
the procedure stopped prematurely because of pain. Some patients 
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may also experience pain radiating to the back of the neck or the 
shoulder area, which is believed to be related to the stimulation 
of nerve plexuses behind the thyroid gland by the US energy. 
Interestingly, in our experience, using a deep cervical nerve block did 
not seem to reduce this specific complaint, whereas lowering the 
ablation power was a more effective method of reducing that type 
of pain.
In terms of the actual procedure, patients are positioned in a 
supine position with their neck slightly extended by placing a pillow 
behind the shoulders. After adequate neck exposure, the treatment 
is carried out with an US-guided HIFU device (EchoPulse, Theraclion, 
Paris, France). This commercially-available device is essentially a US-
guided HIFU machine with a 3-MHz extracorporeal probe, and it 
comprises four parts: an energy generator, a treatment probe, a skin 
cooling device, and a touch-screen monitor for control [23,24]. The 
treatment probe operates on two independent US systems, one for 
real-time imaging guidance and the other as a HIFU transducer. The 
imaging system contains 128 elements arranged in a linear array 
and emits frequencies of 7.5 MHz. The HIFU transducer system 
contains a single element, measuring 60 mm in diameter. It is 
capable of emitting frequencies of 3 MHz of pulses up to 125 W of 
maximum acoustic power, with larger and deeper targets receiving 
higher power. The imaging system is placed right in the middle of 
the probe, meaning that the focal point of treatment is always at the 
Table 1. A comparison of inclusion and exclusion criteria for HIFU ablation of benign thyroid nodules
Study Inclusion criteria Exclusion criteria
Esnault et al. (2011) [25] At least 2 thyroid nodules, with 1 needing surgery Suspicion of malignancy nodule, neck irradiation, 
previous surgery, or previous radioactive iodine 
treatment
Nodule targeted for HIFU located at least 3 mm from the 
trachea, esophagus, recurrent laryngeal nerve, carotid 
artery, and skin
Any cystic components ≥20% or any large calcifications
The nodule selected for HIFU treatment was different 
from the one indicated for surgery.
Patient unable to maintain a stable position with 
hyperextended neck
Korkusuz et al. (2015) [26] Over 18 years old Malignant nodules
At least 1 benign nodule causing neck pain, hoarseness, 
swallowing disorders, discomfort, cosmetic concerns, or 
thyrotoxicosis
Target nodules too close to the trachea or carotid 
arteries
Refusing surgery or radioactive iodine treatment Patients with a contraindication for HIFU (recurrent 
nerve anomalies or target volume)
Kovatcheva et al. (2015) [27] Over 18 years old Head and/or neck disease preventing hyperextension 
of the neck
Presence of 1 or more non-malignant thyroid nodules History of thyroid cancer or other malignant tumors in 
the neck region
Nodule measuring greater than or equal to 10 mm in 3 
orthogonal dimensions on ultrasonography
History of neck irradiation
<30% of the targeted nodule comprising a cystic area Intranodular macrocalcifications precluding treatment 
with HIFU
Nodule considered accessible for HIFU Nodules next to the posterior margin of the thyroid 
lobe with an anteroposterior diameter less than 15 mm
Normal TSH level Pregnancy/lactation
No vocal cord immobility on laryngoscopy Any contraindications related to moderate intravenous 
sedation
Lang et al. (2017) [28,29] Benign cytology and a sonographic pattern with low to 
very low suspicion 
Age ≤18 years old
Nodule causing pressure symptoms Pregnancy or lactation
All 3 dimensions between 10 and 40 mm Indeterminate or malignant nodules
Nodule ≥70% solidity Intranodular macrocalcifications
Nodule within 5-30 mm from the skin History of head and neck irradiation
Normal thyroid function and calcitonin levels History of non-medullary thyroid carcinoma
Pre-existing vocal cord palsy
HIFU, high-intensity focused ultrasound; TSH, thyroid-stimulating hormone.
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the trachea, and 0.5 cm for the recurrent laryngeal nerve [24]. 
However, our recent study suggested that a larger safety distance 
of up to 1.1 cm might be necessary to avoid inadvertent injury to 
the recurrent laryngeal nerve during treatment [30]. A movement 
detector prevents ablation to unmarked sites by interrupting the 
power supply. Cooling of the pre-focal tissue is achieved by a plastic 
balloon placed at the tip of the treatment head, which is filled with 
a cooling liquid at 10°C. This prevents any damage to the pre-focal 
tissues. 
Clinical Experience
Table 2 summarizes the efficacy of HIFU ablation. The first human 
study of the HIFU ablation of thyroid nodules was conducted 
by Esnault et al. [25]. That study was conducted on 25 patients, 
including 5 men and 20 women aged 25-82 years. All 25 patients 
underwent HIFU treatment 2 weeks before surgery for nodular 
goiter. Each specimen was further examined histologically, and the 
center of the US image. 
Under US guidance, the treatment probe is positioned above the 
skin, superficial to the nodule. The computer (Beamotion version 
no. TUS 3.2.2, Theraclion) then automatically generates multiple 
ablation sites on the nodule, with each site measuring 7.3 mm in 
thickness and 5 mm in width (Fig. 1). A HIFU pulse lasting for 8 
seconds, followed by 40 seconds of cooling time, is delivered to 
each ablation site. The length of the cooling time depends on the 
power of the ablation, with a higher power needing a longer time 
for cooling (Video clip 1).
Treatment Safety 
The thyroid gland lies near a few vital structures, including the 
carotid artery, trachea, and recurrent laryngeal nerve [24]. These 
structures are marked and left unablated. A safety distance is 
recommended to prevent the treatment beam from ablating these 
structures: 0.2 cm for the common carotid arteries, 0.3 cm for 
Table 2. A comparison of pre-ablation nodule volume and treatment efficacy following single-session HIFU ablation
Study No. of nodules treated Pre-ablation volume (mL) Efficacy (% reduction from baseline)
Esnault et al. (2011) [25] 22 Range 0.5-2.6 Nodules surgically resected and examined histologically after 2 wk
Korkusuz et al. (2015) [26] 9 Median, 3.5 (0.8-7.7) Median, 48.8 (11.4-75.0) at 3 mo
Kovatcheva et al. (2015) [27] 20 Mean±SD, 4.96±2.79 (1.56-9.35) Mean±SD, 48.7±24.3 at 6 mo (after single ablation)
Lang et al. (2017) [31] 22 Mean±SD, 6.98±4.04 (1.68-16.76) Mean±SD, 68.87±15.27 at 12 mo (following single ablation)
Lang et al. (2017) [23] 73 Range 0.6-39.2 Median±SD, 68.3 (22.77-96.5) at 6 mo (following single ablation)
HIFU, high-intensity focused ultrasound.
Fig. 1. A treatment image captured 
immediately after an 8-second treatment 
pulse. The central panel represents the 
bird-eye view reconstruction of the 
nodule. The empty circles represent the 
non-ablated subunits, while the filled 
circles represent the ablated subunits. 
The presence of hyperechoic marks 
(microbubbles) at the focal point of the 
high-intensity focused ultrasound beams in 
the treatment screen should also be noted. 
Skin
Skin
Reference screen Real-time treatment screen
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specific features of lesions caused by HIFU included the presence of 
coagulative necrosis, multiple fibrotic scars, thrombosis, and a cystic 
area encircling the lesions [25]. Other non-specific lesions included 
non-coagulative necrosis, hemorrhage, nodule detachments, 
cavitations, and cysts [25]. In order to form lesions that were 
suitable for histological examinations, the depth-independent pulse 
acoustic energy was gradually increased, from 35 to 94 J. In 10 
patients, the thyroid nodule demonstrated clear necrosis following 
HIFU treatment. In the other cases, cavitation was observed in 
the nodules, but it was debatable whether the cavitation was 
caused by HIFU or was due to pre-existing lesions. Nonetheless, if 
cavitation is considered a HIFU-induced lesion, the degree of nodule 
destruction ranged from 2% to 80%. The authors concluded that 
HIFU treatment was suitable to treat thyroid nodules. The long-term 
results of HIFU on the thyroid nodules were not discussed in their 
study since all patients underwent thyroidectomy 2 weeks after 
HIFU.
Lang et al. [31] conducted a prospective study investigating the 
first-year efficacy and changes in pressure symptoms and health-
related quality of life (HRQOL) after HIFU treatment of benign thyroid 
nodules. A total of 44 patients were included in their study. Of these 
patients, 22 patients received HIFU treatment, while the other 22 
received active surveillance only. Clinical and US examinations, 
pressure symptom scores, and HRQOL were compared at 3, 6, and 
12 months. In patients who presented with multiple nodules, only 
the largest one was ablated. All nodules in HIFU patients showed a 
reduced volume 1 month after the treatment, with a mean reduction 
of 22.58%±9.23%. Successful ablation, defined as a >50% 
reduction in nodule volume, was achieved in 18 patients (81.8%) 
3 months after the HIFU treatment, with a mean volume reduction 
of 61.54%±16.68%. No further significant reduction in volume 
was observed at 3, 6, and 12 months. Pressure symptoms were 
significantly reduced in HIFU patients, and significant differences in 
pain, general health, social functioning, and role emotional were 
observed between the HIFU group and the active surveillance group. 
The authors concluded that HIFU was a safe, non-invasive treatment 
and led to significant improvements over the active surveillance 
group [31]. A key finding of this study was the relationship between 
nodule volume and ablation success; small pre-ablation volume was 
related to a more successful HIFU ablation [31].
Another study conducted by the same group, Lang et al. [23], 
primarily investigated the treatment of large benign thyroid nodules 
with HIFU. Seventy-three nodules treated with HIFU and followed 
up for more than 6 months were selected. Nodule volume was then 
measured 1 week, 1 month, 3 months, and 6 months after HIFU 
treatment. At 6 months, nodules with a pre-ablation volume of more 
than 30 mL had a mean shrinkage of 48.1%, which was less than 
the shrinkage observed in those less than 10 mL and those between 
10 and 30 mL (77.6% and 67.9% respectively). The overall median 
nodule volume reduction was 68.3% at 6 months after a single 
HIFU ablation session. The authors concluded that the larger the size 
of the nodule, the less the extent of nodule shrinkage. A possible 
explanation for this is an inbuilt limitation of the HIFU device, which 
can only be used to ablate nodules up to a certain size (>3.5 cm to 
4.0 cm) [23].
Korkusuz et al. [26] conducted a study regarding the volume 
reduction of benign thyroid nodules 3 months after a single HIFU 
treatment. Nine patients were included in the study. The volume 
of the thyroid nodules was measured before and 3 months after 
the HIFU therapy. The volume reduction ranged from 11.4% to 
75%, with an overall median nodule volume reduction of 48.8%. 
It was concluded that the current HIFU method was sufficient to 
reduce benign nodule volumes in comparison to other non-invasive 
techniques. 
Kovatcheva et al. [27] conducted a prospective study to assess 
how effective HIFU was for treating benign solid thyroid nodules. 
Twenty patients with euthyroid nodular goiter were included in the 
study. US assessments of these patients were conducted at 1 week, 
1 month, and 3 months after a single HIFU ablation session. At 1 
week, 8 nodules were enlarged, with a mean percentage volume 
increase of 17.2%±9.2%. A mean reduction of 8.7%±6.9% in 
nodule volume was recorded in the other 12 subjects. A mean 
volume reduction of 26.3%±16.9% and 38.5%±21.6% was 
recorded at 1 month and 3 months after HIFU ablation, respectively. 
Sixteen of the 20 patients had a nodule reduction of more than 
30% and were further followed up. A mean volume reduction of 
48.7%±24.3% was measured. It was concluded that a single HIFU 
treatment was effective for reducing the volume of benign thyroid 
nodules.
Vocal Cord Palsy 
Since the recurrent laryngeal nerve runs at the back of the thyroid 
lobe before entering the larynx, vocal cord palsy (VCP) is a potential 
complication after HIFU ablation. Indeed, VCP occurred not 
uncommonly following HIFU treatment in earlier series [32,33]. 
In a recent series of 103 patients who completed single-session 
HIFU ablation on one side of the thyroid gland, four patients 
(3.9%) complained of an immediate voice change after treatment 
(i.e., on day 0 following treatment) and all were later confirmed 
to have a completely paralyzed vocal cord by laryngoscopy [30]. 
Therefore, there was a small but definite risk of VCP following 
HIFU ablation. The likelihood of this complication was thought to 
be related to the focused point of the HIFU beam being close to 
the tracheoesophageal groove where the nerve normally lies [30]. 
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Nevertheless, it is worth pointing out that all of these injuries were 
transient [30].
Changes in Thyroid Function
Although HIFU treatment is commonly used for ablating benign 
thyroid nodules, as with all other treatments, it is associated 
with various side effects, one of which is altered thyroid function 
following treatment [28]. Therefore, thyroid function tests have 
commonly been performed before and after HIFU ablation to 
determine whether HIFU had an effect on thyroid function. Lang 
et al. [28] analyzed 83 patients who received HIFU treatment for a 
symptomatic benign thyroid nodule between 2015 and 2016. After 
excluding patients with suppressed thyroid-stimulating hormone 
(TSH) levels (n=6), those who received more than 1 treatment (n=3), 
and those with elevated anti-thyroid auto-antibodies suggestive of 
lymphocytic thyroiditis (n=2), 72 patients were analyzed. Thyroid 
function was measured on the day before treatment, 1 week after 
treatment, and 3 and 6 months after the HIFU ablation. Serum TSH 
dropped at 1 week, from 1.16 mIU/L at baseline to 0.76 mIU/L, but 
stayed similar at 3 and 6 months, whereas serum fT4 levels rose at 
1 week, from 16.0 to 17.8 pmol/L, but not at 3 or 6 months. Only 
one patient required thyroxine replacement, but that patient had a 
previous lobectomy before ablation. In that series, no patients had 
an autonomously functioning thyroid nodule. Therefore, the authors 
concluded that altered thyroid function after HIFU treatment was 
rare and mild. These findings were similar to those of another study 
by Esnault et al. [25], in which the thyroid function of 22 patients 
was monitored after HIFU. Other than one patient, no significant 
changes in TSH, fT3, or fT4 were observed after the HIFU treatment. 
However, a transient increase in thyroglobulin levels was detected in 
five patients on the day after HIFU treatment. Euthyroidism was also 
achieved in eight patients in the study of Korkusuz et al. [26]. Based 
on the currently available data, we believe that altered thyroid 
function following single-session HIFU ablation is very rare and 
is likely to be self-limiting, particularly in patients with no history 
of thyroidectomy, and would only recommend checking thyroid 
function once at 1-2 months after HIFU ablation.
Discussion
Surgical treatment for thyroid nodules is a well-developed technique. 
However, potential risks such as neck scarring, hoarseness, and 
the need for thyroid hormone replacement therapy have led to the 
introduction of non-invasive therapies into clinical practice [29]. 
Ethanol ablation, LA, microwave ablation, and RFA are the minimally 
invasive treatments in common use today [9,10,34]. Nonetheless, 
the ever-changing medical world has seen the introduction of newer 
techniques, such as HIFU. HIFU ablation could be considered a truly 
non-invasive procedure because it is able to induce irreversible 
tissue necrosis via thermal ablation beneath the skin without skin 
puncture or incision [7]. Moreover, because the entire ablation can 
be programmed, treatment success is thought to be less dependent 
on the skill of the operator [12]. However, it is associated with 
complications. These include burning pain [29,32], pain towards the 
neck and upper back, mild skin redness, and subcutaneous edema 
[29,33].
Transient VCP appears to be the most common complication 
following HIFU treatment of thyroid nodules [30,32,33]. In a small 
series of patients, Leenhardt et al. [32] reported this complication 
in one patient. In a series of 103 patients who underwent HIFU 
ablation on one side of the thyroid gland, four patients (3.9%) 
were reported to have suffered from unilateral VCP afterwards. 
Fortunately, all the injuries recovered fully within a period of 6 
weeks. In that study, the cause of the injury was further investigated, 
and it was found that the measurable distance between the focal 
point of the treatment beam and the tracheoesophageal groove 
(where the recurrent laryngeal nerve was located) was associated 
with the risk of this injury. Therefore, the thermal spread of the beam 
was the likely cause of these temporary nerve injuries [30].
In terms of treatment efficacy, the extent of nodule shrinkage 
following treatment ranged from 45% to 50% in the first 3 to 6 
months (Fig. 2) [23-27,31]. However, it is worth noting that only 
two recent studies have reported outcomes for 6 months or longer 
[27,31]. The rest reported outcomes for up to 3 months [25,26]. 
Consistent with experiences with other types of thermal ablation, the 
treated nodule tended to continually shrink over time, suggesting 
that the trend of nodule shrinkage would tend to continue for the 
first 12 months [31]. However, since nodule regrowth can occur 
following successful LA and RFA (in 5% of cases) [7], studies with 
a longer follow-up period are required [25]. The reported efficacies 
for HIFU were quite variable, but appeared comparable to those for 
other thermal ablation techniques such as RFA, microwave ablation, 
and LA [24]. However, it should be pointed out that the baseline 
nodule characteristics tended to vary across studies, and so a direct 
comparison between techniques was impossible. Recent studies 
seemed to report higher rates of efficacy, perhaps related to the use 
of higher power settings and improved technique. 
It has been observed that HIFU ablation of benign thyroid nodules 
causes a massive release of thyroglobulin into the circulation [29,35]. 
A study conducted by Lang et al. [35] investigated whether the 
initial rise in thyroglobulin levels was correlated with the success of 
treatment (nodule shrinkage at 6 months). A sample of 105 patients 
was selected, and their serum thyroglobulin and anti-thyroglobulin 
antibodies were measured before HIFU treatment and 4 days after. 
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Despite a 7-fold increase in the mean thyroglobulin level 4 days 
after the HIFU ablation, this parameter did not seem to predict the 
success of HIFU for benign thyroid nodules [35]. 
Based on our review, several shortcomings related to HIFU 
ablation are worth highlighting. First, most of the treated nodules 
were relatively small in terms of size and volume [10,11]. On 
average, using a current US-guided device, a 3-cm thyroid nodule 
would take approximately 45-60 minutes for complete ablation, 
while for RFA, microwave ablation, or LA, the procedure would 
normally take between 15 and 20 minutes. Even though it is 
possible to increase the power in order to shorten the treatment 
time, skin burns could become a problem with higher energy, as 
some energy is absorbed by the skin and subcutaneous tissue 
during treatment. Second, many unanswered questions remain, 
since clinical experiences are limited. For example, the longer-
term efficacy of ablation remains unknown, although up to 15%-
20% of nodules can be predicted to show a less-than-adequate 
response (<50% shrinkage at 6 months). Therefore, it is necessary 
to validate the factors related to the efficacy of HIFU (or recurrence 
after HIFU). In other forms of ablation, operator experience, number 
of treatment sessions, tumor vascularity, and delivered energy have 
been implicated as factors affecting efficacy [36]. Third, with the 
currently-available device, treatment pulses can only be applied to 
a single layer with a maximum treatment depth of 2.8 cm under 
the skin. Nodules located in deeper or more posterior parts of the 
thyroid gland are currently not fully treatable by the current HIFU 
device. Moreover, the initial starting cost seemed to be much higher 
than that of other techniques, which was mostly related to the 
Fig. 2. A 37-year-old woman complaining of a growing right 
thyroid swelling. 
A-C. Sagittal ultrasonography of a right solid thyroid nodule 
obtained before treatment (A) and 3 months (B) and 6 months 
(C) after high-intensity focused ultrasound treatment are shown. 
The extent of nodule shrinkage and the echogenic change (from 







Brian H. Lang, et al.
8  Ultrasonography 2017 Oct 10 [Epub] e-ultrasonography.org
start-up cost of the device. Last but not least, HIFU is not a painless 
procedure, and therefore, deep sedation or even general anesthesia 
is often necessary to ensure the success of the procedure.
Conclusion
Despite the relatively limited clinical experiences that have been 
reported from a handful of specialized centers around the world, our 
review suggests that single-session HIFU is a safe and efficacious 
method of treating symptomatic benign thyroid nodules. However, to 
confirm this finding, a larger-scale, multicenter, prospective trial will 
be necessary. In terms of the ablation itself, relative to other thermal 
ablation techniques, there is still much room for improvement in 
terms of shortening the treatment duration and increasing the range 
of treatable nodules.
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Video clip 1. This clip shows a typical treatment cycle of a solid 
thyroid nodule. On the right side of the screen, one can see that 
the nodule or target was isoechoic in appearance and measured 
3.5 cm in its longest diameter. There was a 35-second cooling-
down period before the actual 8-second treatment high-intensity 
focused ultrasound pulse was administered. During the cooling-
down period, the operator may adjust the power of the treatment 
according to the degree to which the patient tolerates it and the 
presence of hyperechoic marks on the screen. In the latter part of 
the clip, following the 8-second treatment pulse, the treatment head 
moved to a different region of the nodule. This cycle continued until 
the planned layer of the nodule had been completely ablated. A 
typical session comprises 50 to 70 treatment cycles, lasting for 40-
50 minutes (https://doi.org/10.14366/usg.17057.v001).
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